

Endoscopy and Systematic Biopsy of Patients with Chronic Gastrointestinal Symptoms Leads to High Discovery Rate of Patients Who Meet Histologic Criteria for Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Nicholas J. Talley MD PhD^{*1}, Amol P. Kamboj MD², William D. Chey MD³, Henrik S. Rasmussen MD PhD², Brian E. Lacy MD PhD⁴, Ikuo Hirano MD⁵, Mirna Chehade MD MPH⁶, Nirmala Gonsalves MD⁵, Kathryn A. Peterson MD⁷; Anthony Lembo MD⁸; Colleen M. Schmitt MD MHS⁹; Marc E. Rothenberg MD PhD¹⁰, Robert M. Genta MD¹¹; Maria A. Pletneva MD PhD⁷; Kevin O. Turner DO¹²; Malika Pasha MBA², Evan S. Dellon MD MPH^{*13}, William J. Sandborn MD^{*14}

¹University of Newcastle, Australia; ²Allakos, Inc., Redwood City, CA; ³University of Michigan, Ann Arbor, MI; ⁴Mayo Clinic Jacksonville, Jacksonville, FL; ⁵Northwestern University Feinberg School of Medicine, Chicago, IL; ⁶Icahn School of Medicine at Mount Sinai, New York, NY; ⁷University of Utah, Salt Lake City, UT; ⁸Beth Israel Deaconess Medical Center, Division of Gastroenterology, Boston, MA; ⁹Galen Medical Group, Chattanooga, TN; ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH; ¹¹Baylor College of Medicine, Houston, TX; ¹²UT Southwestern, Dallas, TX; ¹³University of North Carolina, Chapel Hill, NC; ¹⁴University of California San Diego, La Jolla, CA

DDW 2021

Virtual


May 21st – 23rd 2021

#537

Disclosures

- Dr. Nicholas Talley is a consultant for Allakos, Inc.
- Lirentelimab (AK002) is an investigational drug candidate and is not FDA/EMA approved

Eosinophilic Gastrointestinal Diseases (EGIDs)



EG, EoD, EoE

Chronic Eosinophilic Inflammation of the Stomach, Duodenum, or Esophagus

- Eosinophils and mast cells are important drivers of disease
- Symptoms: abdominal pain, nausea, early satiety, loss of appetite, bloating, abdominal cramping, vomiting, diarrhea, and dysphagia
- No FDA approved treatment for EG, EoD, or EoE
- Current standard of care: diet and/or steroids

ENIGMA: Phase 2 Study of Lirentelimab in EG and/or EoD

INCLUSION CRITERIA

- Patient-reported active moderate-to-severe symptoms per the **EG/EoD Questionnaire**[®]
 - Captures the symptoms of EG/EoD patients on a daily basis
 - Measures 8 symptoms each on a scale of 0-10; Total Symptom Score: (TSS) 80 points
 - Abdominal pain - Loss of appetite
 - Nausea - Abdominal cramping
 - Vomiting - Bloating
 - Early satiety - Diarrhea
 - Symptom criteria: weekly average ≥ 3 to 10 for abdominal pain, nausea, or diarrhea for at least 2 weeks
- Biopsy-confirmed EG and/or EoD
 - **EG**: ≥ 30 eos/hpf in 5 hpfs (stomach)
 - **EoD**: ≥ 30 eos/hpf in 3 hpfs (duodenum)

STUDY DESIGN


- Phase 2 multi-center, randomized, double-blind, placebo-controlled study
- 65 Patients – 3 arms, 4 monthly doses
 - 21 patients 0.3, 1.0, 3.0, 3.0 mg/kg lirentelimab
 - 22 patients 0.3, 1.0, 1.0, 1.0 mg/kg lirentelimab
 - 22 patients placebo
- Primary endpoint: Mean % reduction in tissue eosinophils from baseline to day 99
- Secondary endpoints
 - % Treatment responders ($>75\%$ reduction in tissue eosinophil counts AND $>30\%$ reduction in symptoms (TSS) from baseline to 2 weeks post-last dose)
 - Mean % reduction in TSS from baseline to 2 weeks post-last dose

RANDOMIZED STUDY RESULTS

| Prespecified Endpoints | | lirentelimab (n=39) | Placebo (n=20) |
|----------------------------------|------------|---------------------|----------------|
| 1° - Tissue Eosinophils | % Δ | -95% | +10% |
| | p-value | <0.0001 | - |
| 2° - Treatment Responders | % | 69% | 5% |
| | p-value | 0.0008 | - |
| 2° - TSS | % Δ | -53% | -24% |
| | p-value | 0.0012 | - |

- All primary and secondary endpoints met in the first randomized trial in patients with EG and EoD
- Generally well tolerated

ENIGMA: Unexpectedly High Diagnosis Rate of EG and/or EoD Among Previously Undiagnosed Patients



Suggests significant underdiagnosis of EG and/or EoD

EG and/or EoD Prevalence Study Aim & Design

- **Study Design**

- Prospective, multi-center study to assess the prevalence of EG and/or EoD in symptomatic patients with chronic functional GI symptoms
 - At least a 6-month history of abdominal pain, abdominal cramping, nausea, vomiting, diarrhea, bloating or early satiety without identifiable cause and unresponsive to pharmacologic or dietary intervention and/or
 - a diagnosis of IBS or functional dyspepsia (FD), indicating a chronicity of symptoms
- **An asymptomatic healthy volunteer study was conducted for comparison**

- **Co-Primary Endpoints**



- Proportion of symptomatic patients that underwent biopsy and met the histologic criteria for EG and/or EoD (≥ 30 eos/hpf in 5 gastric or 3 duodenal hpf)
- Proportion of symptomatic patients that underwent biopsy with ≥ 30 mast cells/hpf in 5 gastric hpf and/or ≥ 30 mast cells/hpf in 3 duodenal hpf and < 30 eos/hpf

Symptoms Assessed With the Same PRO Questionnaire Used in ENIGMA

GI Symptom Questionnaire

- Developed in accordance with FDA guidance on PRO development
- Captures the GI symptoms of patients on a daily basis
- Measures symptoms each on a scale of 0-10 for the following:
 - Abdominal pain
 - Nausea
 - Vomiting
 - Early satiety
 - Loss of appetite
 - Abdominal cramping
 - Bloating
 - Diarrhea
- Average daily score of ≥ 3 (on a scale from 0-10) for any individual symptom and a Total Symptom Score ≥ 10
- Same PRO used for asymptomatic controls who had to have an average daily score ≤ 1 for all symptoms and no daily score ≥ 3 on any day for any symptom

Systematic Biopsy and Histopathologic Assessment Protocol for Patients and Controls



Biopsy Protocol

Stomach

- **GASTRIC ANTRUM: 4 biopsies**
(2-5 cm proximal to the pylorus)
- **GASTRIC CORPUS: 4 biopsies**
(2 from the proximal lesser curvature and 2 from the greater curvature)


Duodenum

- **4 biopsies** from the duodenum, 2 each from the descending and horizontal parts

Assessment Protocol


- Biopsy samples were collected and sent to the central lab for fixing and staining and then evaluated by an external expert pathologist, who was blinded to all patient demographic, clinical, and endoscopic data
- Eosinophils and mast cells were counted systematically in a minimum of 5 non-overlapping hpfs in at least 12 biopsies to avoid missing areas of infiltration
- Gastric biopsies were graded using the Sydney System on inflammation, metaplasia, atrophy, and reactive gastropathy; the Marsh Scale Classification was used to grade duodenal samples

High Prevalence of EG and/or EoD in Patients with Chronic GI symptoms



33% (181/556) of patients with chronic functional GI symptoms and 45% (181/405) of patients with moderate-severe symptoms undergoing biopsy met histologic criteria for EG and/or EoD


Consistent EG and/or EoD Discovery Rate Across Sites



| Region | # Sites | Total Patients | EG and/or EoD Pts | EG and/or EoD Rate |
|--------|---------|----------------|-------------------|--------------------|
| 1 | 7 | 131 | 66 | 50% |
| 2 | 5 | 123 | 60 | 49% |
| 3 | 8 | 151 | 55 | 36% |

These Patients had Previously Been Diagnosed with Functional Disorders

Past GI Diagnoses^a in Patients Who Met Histologic Criteria for EG and/or EoD (n=181)




Characteristics of EG and/or EoD Patients

| Patient Characteristics | | Met Histologic ^a Criteria for EG and/or EoD n=181 | ENIGMA n=65 |
|---------------------------|---|--|-----------------|
| Mean age, years (range) | | 45 (19-78) | 41 (18-74) |
| Female sex, % | | 73% | 62% |
| White, % | | 85% | 92% |
| Weight, median, kg | | 83 | 80 |
| Blood eosinophils | Cells/ μ L, median (IQR) | 170 (100-250) | 330 (160-720) |
| | Blood eos \geq 250 cells/ μ L, % | 27% | 65% |
| | Blood eos \geq 500 cells/ μ L, % | 4% | 35% |
| | Blood eos \geq 1500 cells/ μ L, % | 0% | 11% |
| Immunoglobulin E | kU/ μ L, median (IQR) | 34 (14-103) | 141 (44-361) |
| | IgE \geq 70 kU/ μ L, % | 36% | 67% |
| TSS [0-80], mean \pm SD | | 31.3 \pm 11.2 | 31.9 \pm 13.6 |
| History of | GI symptoms, mean years | 11 | 9 |
| | Atopy ^b , % | 48% | 69% |
| | EoE, % | 2% | 54% |


^a Patients who met symptom criteria and \geq 30 eos/hpf in 5 gastric hpf and/or \geq 30 eos/hpf in 3 duodenal hpf

^b Asthma, allergic rhinitis, atopic dermatitis and/or food allergy

Comparable Symptom Profile in EG and/or EoD Patients



Total Symptom Scores and Mean Eosinophil Counts in Patients vs. Controls



45% (181/405) of patients and 6% (2/33) of asymptomatic controls met histologic criteria for EG/EoD (Odds ratio=12.52; 95% CI, 3.0–53.0; $P < 0.001$)

Under-Recognition of EG/EoD in Patients with Chronic GI Symptoms

181 of 405 (45%) patients biopsied with moderate-severe unexplained GI symptoms met strict histologic criteria for EG and/or EoD


EG and/or EoD appear to be more common than previously thought, and should be considered in patients with moderate-severe unexplained GI symptoms

Patients with moderate-severe unexplained GI symptoms are currently not well managed, likely because no approved therapies target cellular drivers of disease

Diagnosis of EG/EoD could lead to targeted therapies addressing pathogenic drivers of symptoms and disease

ENIGMA: Changes in Total Symptom Score

Total Symptom Score – Prespecified Analysis



* p < 0.05

In ENIGMA, patients with EG and/or EoD had a meaningful response to lirentelimab, which continued to improve in an open-label extension

We thank the patients who participated in this study, the investigators, and all study staff